New mRNA drug takes on HER2 cancers in first human trial
NCT ID NCT07334119
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new mRNA-based drug called MT-304, alone or with the immunotherapy nivolumab, in adults with advanced HER2-expressing solid tumors. The main goals are to check safety, find the right dose, and get a first look at whether it shrinks tumors. About 60 participants will receive the drug every two weeks and be closely monitored.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MT-304 (mRNA therapy) and nivolumab
What this could lead to
If it works, this could point toward a new treatment option for advanced HER2-expressing cancers.
What could go wrong
This is a very early Phase 1 trial with only 60 participants, so safety and dosing are still being figured out. It may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-EXPRESSING SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cabrini Health
RECRUITINGMelbourne, Victoria, 3144, Australia
Contact Phone: •••-•••-••••
Contact
-
Calvary Mater Newcastle
RECRUITINGWaratah, New South Wales, 2298, Australia
Contact
Contact Phone: •••-•••-••••
-
Cancer Research SA Pty Ltd
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-••••
Contact
-
Icon Cancer Centre South Brisbane
RECRUITINGSouth Brisbane, Queensland, 4101, Australia
Contact Phone: •••-•••-••••
Contact
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact Phone: •••-•••-••••
Contact
-
Scientia Clinical Research Ltd
RECRUITINGRandwick, New South Wales, 2031, Australia
Contact Email: •••••@•••••
Contact
-
The Kinghorn Cancer Centre
RECRUITINGDarlinghurst, New South Wales, 2010, Australia
Contact Phone: •••-•••-••••
Contact